Cite
HARVARD Citation
Glatt, S. et al. (n.d.). OP0108 Bimekizumab, A Monoclonal Antibody That Inhibits both IL-17A and IL-17F, Produces A Profound Response in both Skin and Joints: Results of An Early-Phase, Proof-of-Concept Study in Psoriatic Arthritis. Annals of the rheumatic diseases. pp. 95-96. [Online].